通过高通量药物筛选鉴定脑啡胺作为胶质母细胞瘤的候选药物

Zhiwei Qiao, T. Kondo
{"title":"通过高通量药物筛选鉴定脑啡胺作为胶质母细胞瘤的候选药物","authors":"Zhiwei Qiao, T. Kondo","doi":"10.2198/JELECTROPH.62.17","DOIUrl":null,"url":null,"abstract":"Glioblastoma (GBM) is the most common malignant primary tumor of the central nervous system in adults. Despite advances in GBM treatment, the prognosis of patients with GBM remains poor and novel drugs are urgently required. In this study, we aimed to identify novel drugs for GBM treatment by using a drug screening approach. To this end, we performed high-throughput screening with 118 drugs, including Food and Drug Administration (FDA)-approved anticancer drugs. We found high inhibition rates (more than 90%) for doxorubicin, bortezomib, and cephalomannine in 6 GBM cell lines. Furthermore, we determined the half-maximal inhibitory concentration (IC50) of cephalomannine and found that the drug has a high potential for anti-GBM activity. Moreover, we noted that cephalomannine inhibited cell proliferation by inducing autophagy. Thus, our results indicate that cephalomannine may be an effective drug candidate for GBM treatment.","PeriodicalId":15059,"journal":{"name":"Journal of capillary electrophoresis","volume":"20 1","pages":"17-20"},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Identification of cephalomannine as a drug candidate for glioblastoma via high-throughput drug screening\",\"authors\":\"Zhiwei Qiao, T. Kondo\",\"doi\":\"10.2198/JELECTROPH.62.17\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Glioblastoma (GBM) is the most common malignant primary tumor of the central nervous system in adults. Despite advances in GBM treatment, the prognosis of patients with GBM remains poor and novel drugs are urgently required. In this study, we aimed to identify novel drugs for GBM treatment by using a drug screening approach. To this end, we performed high-throughput screening with 118 drugs, including Food and Drug Administration (FDA)-approved anticancer drugs. We found high inhibition rates (more than 90%) for doxorubicin, bortezomib, and cephalomannine in 6 GBM cell lines. Furthermore, we determined the half-maximal inhibitory concentration (IC50) of cephalomannine and found that the drug has a high potential for anti-GBM activity. Moreover, we noted that cephalomannine inhibited cell proliferation by inducing autophagy. Thus, our results indicate that cephalomannine may be an effective drug candidate for GBM treatment.\",\"PeriodicalId\":15059,\"journal\":{\"name\":\"Journal of capillary electrophoresis\",\"volume\":\"20 1\",\"pages\":\"17-20\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of capillary electrophoresis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2198/JELECTROPH.62.17\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of capillary electrophoresis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2198/JELECTROPH.62.17","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

摘要

胶质母细胞瘤(GBM)是成人中枢神经系统最常见的原发性恶性肿瘤。尽管GBM的治疗取得了进展,但GBM患者的预后仍然很差,迫切需要新药。在这项研究中,我们旨在通过药物筛选方法确定治疗GBM的新药。为此,我们对118种药物进行了高通量筛选,包括美国食品和药物管理局(FDA)批准的抗癌药物。我们发现在6个GBM细胞系中,阿霉素、硼替佐米和头孢曼碱的抑制率很高(超过90%)。此外,我们测定了头曼氨酸的半最大抑制浓度(IC50),发现该药具有很高的抗gbm活性潜力。此外,我们注意到头甘氨酸通过诱导自噬来抑制细胞增殖。因此,我们的研究结果表明,头啡胺可能是治疗GBM的有效候选药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Identification of cephalomannine as a drug candidate for glioblastoma via high-throughput drug screening
Glioblastoma (GBM) is the most common malignant primary tumor of the central nervous system in adults. Despite advances in GBM treatment, the prognosis of patients with GBM remains poor and novel drugs are urgently required. In this study, we aimed to identify novel drugs for GBM treatment by using a drug screening approach. To this end, we performed high-throughput screening with 118 drugs, including Food and Drug Administration (FDA)-approved anticancer drugs. We found high inhibition rates (more than 90%) for doxorubicin, bortezomib, and cephalomannine in 6 GBM cell lines. Furthermore, we determined the half-maximal inhibitory concentration (IC50) of cephalomannine and found that the drug has a high potential for anti-GBM activity. Moreover, we noted that cephalomannine inhibited cell proliferation by inducing autophagy. Thus, our results indicate that cephalomannine may be an effective drug candidate for GBM treatment.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信